Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 26.10.2026 2 BJU Int 1 BMC Urol 1 Br J Cancer 1 Cancer 1 Cancer Imaging 2 Eur J Radiol 4 Eur Urol 3 Int J Urol 1 J Nucl Med 1 Nat Rev Urol 3 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. SCHMIDT CJ, Bernhardt M, Kristiansen G, Gaertner FC, et al
   Segment-based comparison of multiparametric MRI, Gallium-68-PSMA-PET/CT and combined imaging with histopathology in prostate cancer.
   BJU Int. 2026 Oct 18. doi: 10.1111/bju.70497.
   PubMed         Abstract available
   
   
2. JAHANANDISH H, Sang S, Li CX, Vesal S, et al
   An artificial intelligence model combining MRI and ultrasound images (MRUSuNet) for prostate cancer detection outperforms radiologist MRI interpretation.
   BJU Int. 2026 Oct 20. doi: 10.1111/bju.70491.
   PubMed         Abstract available
   
   

   
   BMC Urol

3. TOBU S, Takahashi H, Isoda H, Fujimoto K, et al
   PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study.
   BMC Urol. 2026;26:254.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. TAWADROS T, Brown MD, Hart CA, Clarke NW, et al
   Editorial Expression of Concern: Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.
   Br J Cancer. 2026 Oct 22. doi: 10.1038/s41416-026-03650.
   PubMed        
   
   

   
   Cancer

5. LAWRENCE L
   Talazoparib plus enzalutamide improved rPFS for patients with androgen pathway modulation-sensitive prostate cancer.
   Cancer. 2026;132:e70589.
   PubMed        
   
   

   
   Cancer Imaging

6. PARK S, Kim TS, Lee SU, Tran NQ, et al
   Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.
   Cancer Imaging. 2026;26:145.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

7. WUNSCH III DC, Esengur OT, Makwana RD, Harmon SA, et al
   Impact of MRI quality on the accuracy of targeted prostate biopsy: A prospective PI-QUAL analysis.
   Eur J Radiol. 2026;205:113254.
   PubMed         Abstract available
   
   
8. LEE YJ, Choi MH, Grimm R, von Busch H, et al
   Performance of a deep learning algorithm on deep learning reconstruction-accelerated prostate biparametric MRI: A preliminary study.
   Eur J Radiol. 2026;205:113227.
   PubMed         Abstract available
   
   

   
   Eur Urol

9. GANDAGLIA G, Weiner AB, Briganti A, Eeles RA, et al
   Epidemiology, Risk Factors, and Prevention of Prostate Cancer.
   Eur Urol. 2026 Oct 23:S0302-2838(26)02435-8. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   
10. HUANG Z, Parsaeian M, Viallon V, Wang Z, et al
    Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.
    Eur Urol. 2026 Oct 22:S0302-2838(26)02358-4. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
11. EKLUND M
    Prostate Cancer Proteomics: Towards Refined Risk Prediction.
    Eur Urol. 2026 Oct 21:S0302-2838(26)02440-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
12. COOPER S, Adebusoye B, Moore CM, Tree AC, et al
    In Response to "Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?" Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016
    Eur Urol. 2026 Oct 20:S0302-2838(26)02441-3. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Urol

13. NAITO Y
    Editorial Comment on: "Cancer-Control Outcomes of Japanese Versus German Metastatic Hormone-Sensitive Prostate Cancer Patients: A Real-World Cross-Country Comparison of Patients Undergoing Combination Therapies".
    Int J Urol. 2026;33:e70675.
    PubMed        
    
    
14. URABE F, Ishiyama Y, Fukuokaya W, Fujita N, et al
    Development and Validation of the JIKEI-YAYOI Score for Predicting Castration Resistance in Metastatic Castration-Sensitive Prostate Cancer Treated With ARSI-Based Doublet Therapy.
    Int J Urol. 2026;33:e70677.
    PubMed         Abstract available
    
    
15. MITSUNARI K, Nakamura Y, Imamura R
    Editorial Comment on Prognostic Stratification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line Androgen Receptor Pathway Inhibitor-Based Combination Therapy.
    Int J Urol. 2026;33:e70674.
    PubMed        
    
    

    
    J Nucl Med

16. HANSEN AR, Pattison DA, Goh JC, Ngai SS, et al
    TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of (212)Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer.
    J Nucl Med. 2026 Oct 23:jnumed.126.274089. doi: 10.2967/jnumed.126.274089.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

17. MELAO BVLA, Jardim DL, Li R, Collins K, et al
    Rare prostate cancer histologies: detection, characteristics and treatment.
    Nat Rev Urol. 2026 Oct 19. doi: 10.1038/s41585-026-01194.
    PubMed         Abstract available
    
    

    
    Prostate

18. BAL ALBAYRAK MG, Korak T, Yanar S, Doganay S, et al
    Hippo Pathway Modulation Alters the Proteome and Migratory Phenotype of Prostate Cancer Cells.
    Prostate. 2026 Oct 22. doi: 10.1002/pros.70271.
    PubMed         Abstract available
    
    
19. ALOUFI WD, Szewczyk-Bieda M, Nabi G, Zhang X, et al
    Subsequent Detection of Clinically Significant Prostate Cancer After Suspicious MRI and an Initial Biopsy Negative for csPCa: A Longitudinal Subgroup Analysis of the MULTIPROS Trial.
    Prostate. 2026 Oct 20. doi: 10.1002/pros.70264.
    PubMed         Abstract available
    
    
20. KARDOUST PARIZI M, Karakiewicz PI, Chlosta P, Nyirady P, et al
    Age Does Not Independently Predict Biochemical Recurrence in Prostate Cancer Following Radical Prostatectomy: A Comparative Analysis of 4223 pT2N0R0 Patients.
    Prostate. 2026 Oct 18. doi: 10.1002/pros.70268.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum